Inhibrxinc Stock Buy Hold or Sell Recommendation
| INBX Stock | USD 34.38 0.25 0.73% |
Given the investment horizon of 90 days and your complete indifference towards market risk, our recommendation regarding InhibrxInc is 'Strong Buy'. Macroaxis provides InhibrxInc buy-hold-or-sell recommendation only in the context of selected investment horizon and investor attitude towards risk assumed by holding INBX positions. The advice algorithm takes into account all of InhibrxInc's available fundamental, technical, and predictive indicators you will find on this site. Key drivers impacting InhibrxInc's buy or sell advice are summarized below:
Real Value 29.8 | Target Price 46.75 | Hype Value 34.13 | Market Value 34.38 | Naive Value 33.02 |
A buy or sell recommendation provided by Macroaxis is an automated directive regarding whether to purchase or sell InhibrxInc given historical horizon and risk tolerance towards InhibrxInc. When Macroaxis issues a 'buy' or 'sell' recommendation for InhibrxInc, the advice is generated through an automated system that utilizes algorithms and statistical models.
InhibrxInc |
Execute InhibrxInc Buy or Sell Advice
The InhibrxInc recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on InhibrxInc. Macroaxis does not own or have any residual interests in InhibrxInc or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute InhibrxInc's advice using the current market data and latest reported fundamentals.
Time Horizon
Risk Tolerance
 |  |
Strong Buy
Market Performance | Very Weak | Details | |
Volatility | Very steady | Details | |
Hype Condition | Stale | Details | |
Current Valuation | Overvalued | Details | |
Odds Of Distress | Average | Details | |
Economic Sensitivity | Almost neglects market trends | Details | |
Investor Sentiment | Impartial | Details | |
Analyst Consensus | Hold | Details | |
Reporting Quality (M-Score) | Unavailable | Details |
InhibrxInc Trading Alerts and Improvement Suggestions
| InhibrxInc generated a negative expected return over the last 90 days | |
| InhibrxInc has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the previous year's revenue of 1.8 M. Net Loss for the year was (241.36 M) with loss before overhead, payroll, taxes, and interest of (107.99 M). | |
| InhibrxInc currently holds about 176.38 M in cash with (193.31 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.52. | |
| Over 87.0% of the company shares are owned by institutional investors | |
| Latest headline from seekingalpha.com: As more rare disease therapies launch, their prices are rising |
InhibrxInc current analysts advice
We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. InhibrxInc analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. InhibrxInc analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Average Consensus Hold
The consensus estimates and target price estimation comprises individual analyst assessments, and may or may not mutch the Macroaxis buy or sell advice. It is determined by taking an average of all analyst recommendations and classifying them as Strong Buy, Buy, Hold, or Sell.
InhibrxInc Returns Distribution Density
The distribution of InhibrxInc's historical returns is an attempt to chart the uncertainty of InhibrxInc's future price movements. The chart of the probability distribution of InhibrxInc daily returns describes the distribution of returns around its average expected value. We use InhibrxInc price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of InhibrxInc returns is essential to provide solid investment advice for InhibrxInc.
| Mean Return | 0.03 | Value At Risk | -1.84 | Potential Upside | 2.25 | Standard Deviation | 1.72 |
Return Density |
| Distribution |
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of InhibrxInc historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.
InhibrxInc Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as InhibrxInc is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading InhibrxInc backward and forwards among themselves. InhibrxInc's institutional investor refers to the entity that pools money to purchase InhibrxInc's securities or originates loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Arrowmark Colorado Holdings, Llc (arrowmark Partners) | 2023-12-31 | 956.9 K | Sofinnova Ventures | 2023-12-31 | 773 K | Capital Research Global Investors | 2023-12-31 | 712.4 K | Bank Of America Corp | 2023-12-31 | 693 K | Geode Capital Management, Llc | 2023-12-31 | 687.4 K | Northern Trust Corp | 2023-12-31 | 313.9 K | Goldman Sachs Group Inc | 2023-12-31 | 306.4 K | Morgan Stanley - Brokerage Accounts | 2023-12-31 | 296.9 K | Partner Fund Management Lp | 2023-09-30 | 288.6 K | Viking Global Investors Lp | 2023-12-31 | 7.2 M | Ra Capital Management, Llc | 2023-12-31 | 4.7 M |
InhibrxInc Cash Flow Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Net Borrowings | 33.8M | 41.4M | 40.0M | 128.9M | 148.2M | 155.6M | |
| Capital Expenditures | 1.8M | 1.4M | 864K | 686K | 4.6M | 4.8M | |
| End Period Cash Flow | 11.5M | 128.7M | 131.3M | 273.9M | 277.9M | 291.8M | |
| Change To Netincome | 6.4M | 4.3M | 16.5M | 20.5M | 23.5M | 24.7M | |
| Change To Inventory | (672K) | (2.5M) | 7.8M | (11.0M) | (9.9M) | (9.4M) | |
| Investments | (1.8M) | (1.4M) | (809K) | (686K) | (4.6M) | (4.4M) | |
| Change In Cash | 9.4M | 117.1M | 2.6M | 142.6M | 4.1M | 3.9M | |
| Free Cash Flow | (33.9M) | (49.3M) | (81.2M) | (116.0M) | (197.9M) | (188.0M) | |
| Depreciation | 1.2M | 1.0M | 1.2M | 1.2M | 1.2M | 1.1M | |
| Other Non Cash Items | 9.6M | 11.6M | 2.7M | 5.1M | 8.2M | 6.1M | |
| Net Income | (51.4M) | (76.1M) | (81.8M) | (145.2M) | (241.4M) | (229.3M) |
InhibrxInc Greeks
Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to InhibrxInc or Biotechnology sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that InhibrxInc's price will be affected by overall stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a InhibrxInc stock's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α | Alpha over NYSE Composite | -0.01 | |
β | Beta against NYSE Composite | 0.40 | |
σ | Overall volatility | 1.26 | |
Ir | Information ratio | -0.04 |
InhibrxInc Volatility Alert
InhibrxInc has relatively low volatility with skewness of 1.47 and kurtosis of 13.15. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure InhibrxInc's stock risk against market volatility during both bullish and bearish trends. The higher level of volatility that comes with bear markets can directly impact InhibrxInc's stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different financial instruments as prices fall.InhibrxInc Fundamentals Vs Peers
Comparing InhibrxInc's fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze InhibrxInc's direct or indirect competition across all of the common fundamentals between InhibrxInc and the related equities. This way, we can detect undervalued stocks with similar characteristics as InhibrxInc or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of InhibrxInc's fundamental indicators could also be used in its relative valuation, which is a method of valuing InhibrxInc by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare InhibrxInc to competition |
| Fundamentals | InhibrxInc | Peer Average |
| Return On Equity | -4.75 | -0.31 |
| Return On Asset | -0.46 | -0.14 |
| Operating Margin | (54.03) % | (5.51) % |
| Current Valuation | 1.55 B | 16.62 B |
| Shares Outstanding | 47.39 M | 571.82 M |
| Shares Owned By Insiders | 19.57 % | 10.09 % |
| Shares Owned By Institutions | 86.55 % | 39.21 % |
| Number Of Shares Shorted | 2.15 M | 4.71 M |
| Price To Book | 38.11 X | 9.51 X |
| Price To Sales | 920.99 X | 11.42 X |
| Revenue | 1.8 M | 9.43 B |
| Gross Profit | (107.99 M) | 27.38 B |
| EBITDA | (218.03 M) | 3.9 B |
| Net Income | (241.36 M) | 570.98 M |
| Cash And Equivalents | 176.38 M | 2.7 B |
| Cash Per Share | 4.52 X | 5.01 X |
| Total Debt | 210.14 M | 5.32 B |
| Debt To Equity | 4.22 % | 48.70 % |
| Current Ratio | 7.51 X | 2.16 X |
| Book Value Per Share | 0.92 X | 1.93 K |
| Cash Flow From Operations | (193.31 M) | 971.22 M |
| Short Ratio | 3.41 X | 4.00 X |
| Earnings Per Share | (5.12) X | 3.12 X |
| Target Price | 35.5 | |
| Number Of Employees | 166 | 18.84 K |
| Beta | 2.92 | -0.15 |
| Market Capitalization | 1.62 B | 19.03 B |
| Total Asset | 307.89 M | 29.47 B |
| Retained Earnings | (613.73 M) | 9.33 B |
| Working Capital | 239.05 M | 1.48 B |
| Net Asset | 307.89 M |
Note: Disposition of 416 shares by Deck Kelly of InhibrxInc at 34.16 subject to Rule 16b-3 [view details]
InhibrxInc Market Momentum
Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as InhibrxInc . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
About InhibrxInc Buy or Sell Advice
When is the right time to buy or sell InhibrxInc? Buying financial instruments such as InhibrxInc Stock isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.| 2021 | 2022 | 2023 | 2024 (projected) | Total Current Liabilities | 22.5M | 27.6M | 56.3M | 59.1M | Other Current Liabilities | 9.6M | 17.2M | 43.3M | 45.5M |
Use Investing Ideas to Build Portfolios
In addition to having InhibrxInc in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Corporate Bonds Funds Thematic Idea Now
Corporate Bonds Funds
Funds or Etfs investing in different types of corporate debt instruments. The Corporate Bonds Funds theme has 45 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Corporate Bonds Funds Theme or any other thematic opportunities.
| View All Next | Launch |
Check out InhibrxInc Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. For more information on how to buy InhibrxInc Stock please use our How to Invest in InhibrxInc guide.Note that the InhibrxInc information on this page should be used as a complementary analysis to other InhibrxInc's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Commodity Channel module to use Commodity Channel Index to analyze current equity momentum.
Complementary Tools for InhibrxInc Stock analysis
When running InhibrxInc's price analysis, check to measure InhibrxInc's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy InhibrxInc is operating at the current time. Most of InhibrxInc's value examination focuses on studying past and present price action to predict the probability of InhibrxInc's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move InhibrxInc's price. Additionally, you may evaluate how the addition of InhibrxInc to your portfolios can decrease your overall portfolio volatility.
| Commodity Directory Find actively traded commodities issued by global exchanges | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. |
Is InhibrxInc's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of InhibrxInc. If investors know InhibrxInc will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about InhibrxInc listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (5.12) | Revenue Per Share 0.038 | Quarterly Revenue Growth 4.964 | Return On Assets (0.46) | Return On Equity (4.75) |
The market value of InhibrxInc is measured differently than its book value, which is the value of InhibrxInc that is recorded on the company's balance sheet. Investors also form their own opinion of InhibrxInc's value that differs from its market value or its book value, called intrinsic value, which is InhibrxInc's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because InhibrxInc's market value can be influenced by many factors that don't directly affect InhibrxInc's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between InhibrxInc's value and its price as these two are different measures arrived at by different means. Investors typically determine if InhibrxInc is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, InhibrxInc's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.